Endonovo Therapeutics Inc. has announced it will donate SofPulse devices to intensive care units and medical professionals for investigational use to evaluate SofPulse PEMF technology’s inflammation reduction effect to determine potential efficacy in reducing symptoms of respiratory inflammation and distress in COVID-19 patients.
 
As of March 15h, more than 160,000 worldwide cases of COVID-19 have been reported and the World Health Organization (WHO) has labeled the spread of this virus a pandemic. Medical researchers who have previously successfully studied SofPulse in trials and clinical studies for reduction of pain and edema postoperatively, as well as for (TBI) traumatic brain injury have identified an anti-inflammatory response through which SofPulse technology may help to mitigate the severe respiratory inflammation observed in some COVID-19 patients.
 
A recent publication in the Journal of Biological Regulators and Homeostatic Agents proposes the role of inflammation in coronavirus infection.
 
Endonovo Chief Medical Officer Dr. Nev Zubcevik stated, “COVID-19 has been shown to be causing a release of pro-inflammatory cytokines which contribute to overwhelming inflammation termed a “cytokine storm” in the respiratory system leading to worsened clinical outcomes. The SofPulse Pulsed Electromagnetic Field device is a U.S. Food and Drug Administration-cleared for post-operative management of pain and edema where clinical analysis has shown that the primary mechanism of action is noninvasive reduction of pro-inflammatory cytokine Interleukin 1 Beta and improvement of circulation in tissues. In clinical studies, SofPulse PEMF technology is proven to reduce IL-1 beta by 275 percent at the 18-hour mark after surgery. This is the same interleukin response that has been implicated in the heightened inflammatory response resulting from the COVID-19 infection leading to increases in morbidity and mortality rates.” 

“Although there is no clinical trial or test proving the efficacy of SofPulse in treating respiratory inflammatory conditions, we have observed success in clinical trials using SofPulse to mitigate the release of inflammatory response factors,” Dr. Zubcevik added. “In donating SofPulse units to intensive care units for investigational use in treating patients who are severely ill from COVID-19, Endonovo and myself are hopeful that the SofPulse can be utilized to help reduce the severity of inflammation symptoms in the lungs, much like it does in post-operative wounds, reducing morbidity and mortality and yielding faster recovery.” 
 
Endonovo CEO Alan Collier said, “We are optimistic that donating SofPulse PEMF technology for investigational use and doing what we can do to help the U.S. response to the COVID-19 pandemic will assist infectious disease units and medical professionals treating patients diagnosed with COVID-19 in a positive manner. Endonovo is not in a position to comment on the efficacy or possible benefits SofPulse may provide against COVID-19 at this time. However, we believe the inflammation caused by coronavirus may be inhibited by SofPulse’s PEMF technology. Additionally, in all of the years that SofPulse has been used, there have been no negative effects or contraindications from use of SofPulse in any area tested or when applied during medical treatments. Endonovo wants to do its humanitarian duty by donating SofPulse units for investigational use only to possibly help to reduce mortality rates as we fight this battle with COVID-19.”
 
Sofpulse donations are only to hospitals treating patients in critical care.